The coincidence of chromosome 15 aberrations and β2-Microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

Author(s): Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, et al.

Abstract

Purpose: Total loss of surface presentation of human leukocyte antigen (HLA) class I molecules, protecting tumor cells from the recognition by cytotoxic host CD8+ T cells, is known to be caused by mutations in the β2-microglobulin (β2m) gene. We asked whether abnormalities of chromosome 15, harboring the β2m gene on 15q21, in addition to β2m gene mutations, are causative for the HLA class I–negative phenotype of melanoma cells.

Experimental Design: To answer this, we established primary cell lines from the β2m-negative metastatic melanoma tissues of four different patients and analyzed them for β2m gene mutations and chromosome 15 aberrations, the latter by loss of heterozygosity analysis, fluorescence in situ hybridization (FISH), and multicolor FISH.

Results: Mutations at the β2m gene level were detected in all cell lines. The loss of heterozygosity analysis of microsatellite markers located on chromosome 15 in three of the four cell lines pointed to an extensive loss of chromosome 15 material. Subsequent molecular cytogenetic analysis revealed the coexistence of apparently normal and rearranged versions of chromosome 15 in three cell lines whereas the fourth cell line solely showed rearranged versions. Two of the four cell lines exhibited a special type of intrachromosomal rearrangement characterized by FISH signals specific for the subtelomeric region of 15q at both ends of the chromosome and one centromeric signal in between.

Conclusions: Our data indicate that the complete loss of HLA class I expression in melanoma cells is due to the coincidence of the following mutational events: (a) chromosome 15 instability associated with an extensive loss of genetic material and (b) β2m gene mutations.

Similar Articles

Role of altered expression of HLA class I molecules in cancer progression

Author(s): Aptsiauri N, Cabrera T, Mendez R, Garcia-Lor A, Ruiz-Cabello F, et al.

β-Arrestin-dependent, G protein-independent ERK1/2 activation by the 2-adrenergic receptor

Author(s): Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al.

Human T cell responses against melanoma

Author(s): Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P

Mutations in GNA11 in Uveal Melanoma

Author(s): Van Raamsdonk C, Griewank K, Michelle B, Crosby MB, Garrido MC, et al.

Cohesin‐SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres

Author(s): Remeseiro S, Cuadrado A, Carretero M, Martínez P, Drosopoulos WC, et al.

MDM4 is a key therapeutic target in cutaneous melanoma

Author(s): Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele A, et al.

Epithelial–mesenchymal transition in cancer development and its clinical significance

Author(s): Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al.

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

Author(s): Kokkola R, Andersson A, Mullins G, Östberg T, Treutiger CJ, et al.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Author(s): Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al.

The epithelial-mesenchymal transition generates cells with properties of stem cells

Author(s): Mani A, Guo W, Liao MJ, Eaton E, Ayyanan A, et al.

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Author(s): Azuma T, Yao S, Zhu G, Flies A, Flies S, et al.

Breast cancer version 3

Author(s): Gradishar W, Anderson B, Blair S, Burstein H, Cyr A, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper K, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Author(s): Twyman-Saint VC, Rech AJ, Maity A, Rengan R, Pauken KE, et al.

Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion

Author(s): Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D

Immune cell promotion of metastasis

Author(s): Kitamura T, Qian BZ, Pollard JW

FOXP3+regulatory T cells affect the development and progression of hepatocarcinogenesis

Author(s): Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al.

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

Author(s): Dworkin AM, Spearman A, Tseng S, Sweet K, Amanda AE

Epithelial-mesenchymal transitions in development and disease

Author(s): Thiery JP, Acloque H, Huang R, Nieto A

Molecular biomarker in prostate cancer: The role of CpG island hypermethylation

Author(s): Bastian P, Yegnasubramanian S, Palapattu G, Rogers C, Lin X, et al.

Molecular epigenetics and genetics in neuro-oncology

Author(s): Nagarajan R, Costello J